ASCL1 and neoplasm: By dynamically altering cell states, inducing treatment escape‐associated TFs (such as SOX2, ASCL1), and activating pathways like PI3K/AKT and MYC, the tumour further enhances its ability to adapt to immune attack and metabolic stress.